2025-09-15 - Analysis Report
Okay, here's a comprehensive analysis of Tempus AI (TEM) based on the data you provided. I will present the key numbers first, followed by an analysis of each section and an overall summary.

## Tempus AI (TEM) Analysis

**Ticker:** TEM
**Company:** Unknown Company (Focus on data analysis)

### 1. Performance vs. S&P 500 (VOO)

*   **TEM Cumulative Return:** 56.43%
*   **VOO Cumulative Return:** 24.05%
*   **Absolute Divergence (Current):** 33.2%
*   **Relative Divergence:** 45.8 (Meaning the current divergence is at the 45.8th percentile of its historical range)
*   **Divergence Range:** Min: -25.6, Max: 102.9

**Analysis:**

*   TEM has significantly outperformed the S&P 500 (VOO) over the period covered by the data.
*   The current divergence is positive, indicating TEM's superior performance. However, a relative divergence of 45.8 suggests that this outperformance is not at its peak compared to its historical range.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha   | Beta   | Cap(B) |
|------------|---------|-------|---------|--------|--------|
| 2023-2025  | 56.0%   | 75.0% | 33.0%   | -0.0   | 15.0   |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):** A very high CAGR of 56% indicates strong growth.
*   **MDD (Maximum Drawdown):** A high MDD of 75% suggests significant volatility and risk.
*   **Alpha:** The positive alpha of 33% indicates that TEM has outperformed its benchmark on a risk-adjusted basis.
*   **Beta:** A beta close to 0.0 suggests that TEM's price is not strongly correlated with the overall market. This could indicate that it is influenced by company-specific factors rather than broad market trends.
*   **Cap(B):** A market capitalization of $15 billion suggests a mid- to large-cap company.

### 2. Recent Price Action

*   **Current Price:** $86.38
*   **Previous Close:** $88.78
*   **Price Change:** -2.7%
*   **5-Day Moving Average:** $82.91
*   **20-Day Moving Average:** $77.86
*   **60-Day Moving Average:** $66.98

**Analysis:**

*   The current price is below the previous close, indicating a recent price decrease.
*   The price is above all three moving averages (5, 20, and 60-day), suggesting an overall upward trend. The 5-day moving average is higher than the 20-day, which is higher than the 60-day, further reinforcing the bullish trend.

### 3. Market Risk Indicator (MRI) and Other Indicators

*   **Market Risk Indicator (MRI):** 0.3233 (Low Risk)
*   **RSI:** 58.38
*   **PPO:** 0.587
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (2 shares - Caution - MRI:0.33)
*   **20-Day Relative Divergence Change:** +7.2 (Short-term Increase)
*   **Expected Return:** NaN

**Analysis:**

*   **MRI:** A low MRI of 0.3233 suggests that the overall market risk is currently low.
*   **RSI:** An RSI of 58.38 indicates that the stock is neither overbought nor oversold.
*   **PPO:** A PPO of 0.587 suggests that the short-term moving average is slightly above the long-term moving average, indicating a potential upward trend.
*   **Hybrid Signal:** The signal suggests using 80% of available cash to buy TEM, but with a caution due to the MRI.
*   **Recent Relative Divergence Change:** An increase of 7.2 in the 20-day relative divergence suggests that TEM has been outperforming the S&P 500 recently.
*   **Expected Return:** NaN (Not a Number) indicates that the expected return data is not available. This could be due to insufficient data or limitations in the model.

### 4. Recent News & Significant Events

*   **[2025-09-12]** Tempus AI (TEM) Touches 7-Month High on Pixel FDA Approval
*   **[2025-09-12]** Tempus (TEM) Stock Jumps 13.6%: Will It Continue to Soar?
*   **[2025-09-11]** Why Tempus AI Stock Soared Nearly 14% Higher Today
*   **[2025-09-11]** Northwestern Medicine Integrates Tempus AI’s “David” Clinical Assistant into EHR Platform
*   **[2025-09-11]** Tempus AI Surges, Flirting With A Profit-Taking Zone, On A Fresh FDA Move
*   **[2025-09-11]** Tempus AI Gains FDA Clearance For Updated Pixel To Boost Accuracy And Efficiency In Cardiac Imaging

**Analysis:**

*   The recent news is overwhelmingly positive. FDA approval for "Pixel" and integration of "David" clinical assistant are major catalysts, leading to significant price jumps. The headlines suggest strong momentum and potential for continued growth, but also hint at possible profit-taking.

### 4-2. Analyst Opinions

*   **Consensus:** Buy (2.15 on a scale of 1 to 5)
*   **Number of Opinions:** 11
*   **Target Price (Avg/High/Low):** $73.45 / $98.00 / $60.00

**Analysis:**

*   The analyst consensus is "Buy," indicating a positive outlook for the stock.
*   The average target price of $73.45 is *below* the current price of $86.38, suggesting that analysts, on average, believe the stock is currently overvalued. However, the high target price of $98.00 offers a more optimistic view. The range between high and low target prices also indicates uncertainty among analysts.
*   **Recent Rating Changes:** No Changes

### 5. Recent Earnings Analysis

| 날짜       | EPS    | 예상 EPS |
|------------|--------|----------|
| 2025-08-08 | -0.22  | -0.23    |
| 2025-05-06 | -0.24  | -0.26003 |
| 2025-02-24 | -0.18  | -0.15    |
| 2024-11-04 | -0.25  | -0.26608 |
| 2024-08-06 | -0.63  | -0.59    |

**Analysis:**

*   TEM has consistently reported negative EPS (Earnings Per Share), indicating that the company is not yet profitable.
*   However, in most recent quarters (2025-08-08, 2025-05-06, 2024-11-04), the reported EPS has been *higher* than the expected EPS, suggesting that TEM is performing better than anticipated by analysts.
*   2025-02-24 had a negative surprise where the reported EPS was lower than expected.

### 6. Financial Information

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-06-30 | $0.31B  | 61.99%        |
| 2025-03-31 | $0.26B  | 60.69%        |
| 2024-12-31 | $0.20B  | 60.83%        |
| 2024-09-30 | $0.18B  | 58.50%        |
| 2024-06-30 | $0.17B  | 45.50%        |

| Quarter    | Equity  | ROE        |
|------------|---------|------------|
| 2025-06-30 | $0.31B  | -13.84%    |
| 2025-03-31 | $0.33B  | -20.86%    |
| 2024-12-31 | $0.06B  | -23.10%    |
| 2024-09-30 | $0.05B  | -141.16%   |
| 2024-06-30 | $0.10B  | -562.04%   |

**Analysis:**

*   **Revenue:** Revenue is consistently increasing, indicating strong growth in sales.
*   **Profit Margin:** The profit margin is high (above 60% in recent quarters), suggesting that TEM has a strong pricing power or efficient cost management.
*   **Equity:** Equity has increased significantly over the past year.
*   **ROE (Return on Equity):** ROE is negative, which is consistent with the negative EPS. This indicates that TEM is not generating profits relative to its equity. The large negative values indicate significant losses.

### 7. Overall Analysis and Summary

Tempus AI (TEM) is a company exhibiting strong growth potential and significant volatility.

**Key Positives:**

*   **Outperformance:** Significant outperformance compared to the S&P 500.
*   **High Growth:** Rapid revenue growth and a high CAGR suggest strong market demand for TEM's products/services.
*   **High Profit Margins:** Indicate efficient operations and/or strong pricing power.
*   **Recent Positive News:** FDA approvals and partnerships are major catalysts driving the stock price.
*   **Analyst Consensus:** Overall positive analyst sentiment ("Buy" rating).
*   **Beating EPS Estimates:** Recent earnings reports have generally exceeded expectations.
*   **Low Market Risk Indicator:** Suggests a favorable environment for growth stocks.

**Key Negatives:**

*   **High Volatility:** The high MDD (75%) indicates significant risk.
*   **Unprofitable:** Consistent negative EPS and ROE.
*   **Overvalued:** Average analyst target price is below the current price.
*   **Negative Earnings Surprises:** Occasional misses on EPS estimates.

**Overall Recommendation:**

TEM appears to be a high-growth, high-risk investment. The recent positive news and strong revenue growth are encouraging. However, the lack of profitability and high volatility should be considered. It is important to carefully weigh your risk tolerance before investing in TEM. The mixed signals from analysts (Buy rating but lower average target price) suggest caution.

**Important Considerations:**

*   **Profitability:** Monitor TEM's progress toward profitability. Achieving positive EPS and ROE would be a significant milestone.
*   **Volatility:** Be prepared for potentially large price swings.
*   **Analyst Ratings:** Keep an eye on analyst ratings and target price revisions.
*   **Market Conditions:** Consider the overall market environment and its potential impact on growth stocks.

I hope this comprehensive analysis is helpful.
